Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain & Spasticity Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GlyT2/SLC6A5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GlyT2/SLC6A5 Recombinant Loops / ECD-Fc Sequence Verified. High Purity (>95%). HEK293 Expressed (Native Glycosylation). |
View SLC6A5 Products |
| Gene Delivery | GlyT2/SLC6A5 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Crucial for preserving 12-TM native conformation. |
View SLC6A5 Products |
| Benchmark Ab | Anti-GlyT2/SLC6A5 Recombinant Antibody Sequence verified positive control for validation assays. |
View SLC6A5 Products |
| Validator | GlyT2/SLC6A5 siRNA Set Target-specific knockdown validation in cell-based assays. |
View SLC6A5 Products |
| Related Target A | GlyT1/SLC6A9 Essential counter-screening target to ensure drug selectivity and avoid respiratory side effects. |
View SLC6A9 Products |
| Related Target B | GLRA1 (Glycine Receptor Alpha 1) Downstream functional target in the glycinergic inhibitory pathway. |
View GLRA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-TM Conformation Maintenance | Lentivirus Premade Particles for stable host cell expression, ensuring correct folding of all 12 transmembrane domains. |
| Selectivity Counter-Screening | Verified GlyT1 (SLC6A9) and GlyT2 (SLC6A5) cell-based expression systems to rule out off-target transporter inhibition. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant control proteins included. |
| False Positives | Target-specific validated siRNA included for gene knockdown specificity checks. |
Live GlyT2/SLC6A5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GlyT2/SLC6A5 therapeutics is intensifying, with major players shifting focus from traditional non-selective pain therapies to highly selective GlyT2 allosteric modulators and targeted small molecules. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimal selectivity over GlyT1 to minimize motor and respiratory side effects while maximizing analgesic efficacy in neuropathic pain.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Inhibitors) | Vivozon, Organon | Post-operative Pain, Neuropathic Pain | Selectivity Assay (Need GlyT1 vs GlyT2 comparative cell lines) |
| Allosteric Modulators | Academic/Biotech Consortia | Spasticity, Hyperekplexia research | Conformation-locked functional screening (Need Lentivirus-driven stable cell lines) |
| Gene Therapy / RNAi | Preclinical programs | Chronic Intractable Pain | Knockdown Verification (Need sequence-verified siRNA controls) |